Govt plans central oversight of antimicrobials, boost bulk drug supply

The Health Ministry on Thursday proposed amendments to the New Drugs and Clinical Trials Rules, 2019, to bring antimicrobial products under Central regulatory oversight.
The ministry initiated the move amid concerns that authorities grant manufacturing licences for antimicrobial products without adequate regulatory scrutiny, including mandatory assessments such as bioavailability/bioequivalence and stability studies.
The ministry said the absence of these assessments could compromise the quality, safety and efficacy of antimicrobial products. Substandard or ineffective antimicrobials can also contribute to the emergence and spread of antimicrobial resistance, putting patient safety at risk, according to an official statement.
The proposed amendment seeks to bring antimicrobials under the regulatory framework that governs new drugs through the New Drugs and Clinical Trials Rules, 2019.
“Accordingly, manufacturers would need to secure permission from the Central Licensing Authority (CLA) before approaching the concerned State Licensing Authority (SLA) for a manufacturing licence. This measure is expected to strengthen central regulatory oversight and help ensure the quality, safety and efficacy of antimicrobial products,” the statement said.
The ministry has issued a draft notification to invite objections and suggestions from stakeholders and members of the public before the Central Government finalises the proposed amendment.
Separately, the ministry has proposed amendments to the Drugs Rules, 1945, to introduce separate application and licence forms for the wholesale sale of bulk drugs, including active and inactive bulk substances.
Currently, a common licence covers the wholesale sale of both pharmaceutical formulations and bulk drugs.
The proposed changes aim to establish a dedicated licensing framework for bulk drugs, allowing authorities to exercise more focused regulatory oversight over their wholesale distribution and strengthen accountability across the pharmaceutical supply chain, the ministry said.
Under the proposed framework, wholesalers would have to specify the categories of bulk drugs they handle, including substances covered under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985.
The ministry also proposed requiring wholesalers to conduct bulk drug sales under the personal supervision of a competent person to strengthen accountability in the handling and distribution of these substances.
